DEA's proposed telehealth rules pull back COVID-era remote prescribing flexibilities - Fierce Healthcare
DEA proposes rolling back COVID-era telehealth prescribing flexibilities for controlled substances, requiring in-person visits for most prescriptions.
Aforeworn detected this change in the Telehealth Cross-State Licensing space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Telehealth platforms, virtual specialty clinics, behavioral-health providers, e-prescribers should confirm how it applies to their specific situation before acting. There is a time constraint attached: Proposed rule comment period ends soon; final rule expected within months; compliance likely required within 30-60 days after final rule.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Telehealth Cross-State Licensing continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
DEA proposes to end the temporary waiver allowing remote prescribing of controlled substances without an initial in-person visit, reverting to pre-pandemic Ryan Haight Act requirements.
Who it affects
Telehealth platforms, virtual specialty clinics, behavioral-health providers, e-prescribers
What you must do
Prepare to transition patients to in-person visits or find a DEA-registered prescriber for initial evaluations; consider alternative non-controlled substance treatments.
Deadline
Proposed rule comment period ends soon; final rule expected within months; compliance likely required within 30-60 days after final rule.
Never miss a change like this again
Aforeworn watches Telehealth Cross-State Licensing around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Telehealth Cross-State Licensing
- DEA Proposes a Special Registry for Telehealth Providers of Controlled Substances - MedPage Today
- DEA Releases Long-Awaited Telehealth Special Registration Proposal, but Adoption Is Uncertain - McDermott+
- DEA Extends Telemedicine Flexibilities for Ketamine Prescribing: What Clinics Need to Know in 2026 - JD Supra
- Georgia medical board will limit virtual prescriptions - Atlanta Journal-Constitution
- DEA Proposed Telemedicine Prescribing Rule Could Burden Hospice Physicians and Hospice Operations - Morgan Lewis